{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:07:55Z","timestamp":1765728475144},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.diagmicrobio.2012.12.002","type":"journal-article","created":{"date-parts":[[2013,1,26]],"date-time":"2013-01-26T16:45:22Z","timestamp":1359218722000},"page":"298-303","source":"Crossref","is-referenced-by-count":16,"title":["Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials"],"prefix":"10.1016","volume":"75","author":[{"given":"Andrew F.","family":"Shorr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marin","family":"Kollef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul B.","family":"Eckburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily","family":"Llorens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. David","family":"Friedland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.diagmicrobio.2012.12.002_bb0005","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1440-1843.2011.02017.x","article-title":"A prospective cohort study of healthcare visits and rehospitalizations after discharge of patients with community-acquired pneumonia","volume":"16","author":"Adamuz","year":"2011","journal-title":"Respirology"},{"issue":"7\u20138","key":"10.1016\/j.diagmicrobio.2012.12.002_bb0010","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.micinf.2012.01.012","article-title":"Streptococcus pneumoniae: the evolution of antimicrobial resistance to beta-lactams, fluoroquinolones and macrolides","volume":"14","author":"Cornick","year":"2012","journal-title":"Microbes Infect"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2012.12.002_bb0015","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1128\/AAC.01773-09","article-title":"Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing","volume":"55","author":"Croisier-Bertin","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2012.12.002_bb0020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3810\/pgm.2010.03.2130","article-title":"Burden of community-acquired pneumonia in North American adults","volume":"122","author":"File","year":"2010","journal-title":"Postgrad Med"},{"issue":"Suppl 3","key":"10.1016\/j.diagmicrobio.2012.12.002_bb0025","first-page":"iii19","article-title":"FOCUS 1: A randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.12.002_bb0030","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/657313","article-title":"Integrated analysis of FOCUS 1 and FOCUS 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia","volume":"51","author":"File","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"52","key":"10.1016\/j.diagmicrobio.2012.12.002_bb0035","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1128\/AAC.00149-08","article-title":"In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States","volume":"9","author":"Ge","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.12.002_bb0040","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/650496","article-title":"Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post\u20137-valent conjugate vaccine era","volume":"201","author":"Gertz","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2012.12.002_bb0045","series-title":"National Hospital Discharge Survey: 2007 Summary. National Health Statistics Reports; no 29","author":"Hall","year":"2010"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2012.12.002_bb0050","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s10156-004-0309-3","article-title":"In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599","volume":"10","author":"Iizawa","year":"2004","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.12.002_bb0055","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMsa0803563","article-title":"Rehospitalizations among patients in the Medicare Fee-for-Service program","volume":"360","author":"Jencks","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2012.12.002_bb0060","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.diagmicrobio.2010.08.024","article-title":"Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998\u20132009) [letter]","volume":"68","author":"Jones","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2012.12.002_bb0065","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1128\/AAC.00019-10","article-title":"Affinity of ceftaroline and other \u03b2-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae","volume":"54","author":"Kosowska-Shick","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.diagmicrobio.2012.12.002_bb0070","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: A randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.diagmicrobio.2012.12.002_bb0075","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2012.12.002_bb0080","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/jac\/dkp503","article-title":"Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae","volume":"65","author":"Moisan","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.12.002_bb0085","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1086\/528996","article-title":"Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005","volume":"197","author":"Moore","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2012.12.002_bb0090","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1055\/s-0029-1202937","article-title":"Community-acquired pneumonia: the U.S. perspective","volume":"30","author":"Niederman","year":"2009","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.diagmicrobio.2012.12.002_bb0095","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention","volume":"163","author":"Niederman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 3","key":"10.1016\/j.diagmicrobio.2012.12.002_bb0100","first-page":"iii53","article-title":"Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia","volume":"66","author":"Rank","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.12.002_bb0105","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1086\/595857","article-title":"Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004\u20132005","volume":"48","author":"Richter","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2012.12.002_bb0110","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1128\/AAC.49.8.3501-3512.2005","article-title":"Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains","volume":"49","author":"Sader","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2012.12.002_bb0115","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1128\/AAC.06185-11","article-title":"Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic\/pharmacodynamic model","volume":"56","author":"Steed","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.12.002_bb0120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2174\/1874467210801010068","article-title":"Immunomodulatory properties of antibiotics","volume":"1","author":"Tauber","year":"2008","journal-title":"Curr Mol Pharmacol"},{"key":"10.1016\/j.diagmicrobio.2012.12.002_bb0125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/thx.2009.129502","article-title":"Clinical and economic burden of community-acquired pneumonia among adults in Europe","volume":"67","author":"Welte","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.diagmicrobio.2012.12.002_bb0130","series-title":"Deaths: final data for 2007. National Vital Statistics Report. Vol 58 no 19","author":"Xu","year":"2010"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889312005184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889312005184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T19:01:31Z","timestamp":1562612491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889312005184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0732889312005184"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2012.12.002","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}